Allon Appoints Biotech Leader to its Board of Directors
Allon Therapeutics Inc. announced the appointment of Michael Aldridge as a director of the Company. Michael currently serves as Executive Director and member of the Board of biopharmaceutical company Xenome Limited. Aldridge replaces Michael O’Brian, who is retiring from the Board of Directors after serving since 2004.
In May 2010 Aldridge joined Xenome, a pain company focused on the development of peptide-based therapeutics with a product in late-stage clinical trials. From 2003 to 2008, he led Peplin, Inc., a public company that grew under his leadership into a global dermatology company with two skin cancer products in late-stage clinical trials. Peplin was sold to LEO Pharma A/S, a European dermatology company, for US$287.5 million in cash. Previous to his leadership at Peplin, Aldridge had a successful investment banking career in Australia, New York, and London.
Other news from the department people
